Sarepta Therapeutics, Inc. (SRPT)
| Market Cap | 2.05B |
| Revenue (ttm) | 2.23B |
| Net Income (ttm) | -248.39M |
| Shares Out | 98.28M |
| EPS (ttm) | -2.59 |
| PE Ratio | n/a |
| Forward PE | 14.87 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,299,478 |
| Open | 21.17 |
| Previous Close | 21.56 |
| Day's Range | 20.51 - 21.31 |
| 52-Week Range | 18.30 - 173.25 |
| Beta | 0.60 |
| Analysts | Buy |
| Price Target | 75.65 (+262.05%) |
| Earnings Date | Aug 6, 2025 |
About SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 24 analysts, the average rating for SRPT stock is "Buy." The 12-month stock price forecast is $75.65, which is an increase of 262.05% from the latest price.
News
SRPT NOTICE: Did Sarepta Therapeutics, Inc. Mislead Investors about the Safety of Elevidys? Contact BFA Law if You Lost Money (NASDAQ:SRPT)
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) for potential violations of...
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. is being Investigated for Securities Fraud after Second Elevidys Death; Investors with Losses are Notified to Contact BFA Law
NEW YORK--(BUSINESS WIRE)---- $SRPT #Attorney--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) for potential violations...
SRPT Stock: What's Happening With Sarepta Therapeutics?
Sarepta Therapeutics (NASDAQ: SRPT) suffered a devastating blow on Monday, June 16 when its stock plummeted 42% following news of a second patient death linked to its Duchenne muscular dystrophy gene ...
Mizuho's Jared Holz on what is next for Sarepta after second death connected to gene therapy
Jared Holz, Mizuho, joins 'Fast Money' to talk the fallout for Sarepta after another death related to its muscular dystrophy gene therapy.
Down To Levels Not Seen Since 2016: Initiating Sarepta With A Buy
Sarepta Therapeutics, Inc. plunged over 47% after a second ELEVIDYS-related patient death, raising serious safety concerns and leading to trial suspensions. Despite the negative headlines and slashed ...
Sarepta's gene therapy medicine kills patient, CEO suspends full year guidance
CNBC's Angelica Peebles reports on the latest news regarding Sarepta.
SRPT Down Near 9-Year Low, CSCO Upgrade, ROKU Using AMZN Ads
Sarepta Therapeutics (SRPT) sold off more than 40% after suspending its Elevidys Duchenne muscular dystrophy drug, which was linked to two fatal liver failure cases. Diane King Hall break takes a clos...
Sarepta Therapeutics' Elevidys Liver Deaths Trigger Selloff, A Contrarian Opportunity
Sarepta's stock has plunged due to safety concerns with ELEVIDYS, including two deaths in non-ambulatory DMD patients and regulatory uncertainty. Despite these setbacks, ELEVIDYS remains effective for...
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining more than 150 points on Monday.
Sarepta Stock Crashes After Death of Second Patient Receiving Its Gene Therapy
A second patient receiving its experimental gene therapy Elevidys has died from liver failure, raising serious questions on the drug's outlook.
Sarepta shares tumble on second patient death after gene therapy treatment
Shares of Sarepta Therapeutics plunged 34% in premarket trading on Monday, a day after the company disclosed a second case of patient death due to acute liver failure after receiving its gene therapy ...
Sarepta Therapeutics: Rebuilding The Thesis After Hitting Rock Bottom
Sarepta's stock collapsed due to ELEVIDYS safety concerns, regulatory setbacks, and reduced revenue guidance, but I see potential upside at current prices. ELEVIDYS's safety profile, especially in non...
Sarepta reports second case of liver failure death after its gene therapy treatment
Sarepta Therapeutics on Sunday said there had been a second reported case of acute liver failure resulting in death after a patient received the company's gene therapy for a rare form of muscular dyst...
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (delandistrog...
U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta's Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the rAAVrh74 viral vector used in the inve...
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS (delandistrogen...
Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported new results from Study 9001-103. Also known as E...
Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new data from Part 2 of the EMBARK study that c...
Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the Japanese Ministry of Health, Labour, a...
Top 3 Health Care Stocks That Are Preparing To Pump This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Sarepta Therapeutics to Present at the BofA Securities Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi...
Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating
Sarepta Therapeutics, Inc.'s gene therapy SRP-9003 for LGMD 2E/R4 subtype progresses, with potential BLA submission in H2 2025, possibly boosting shareholder value. SRPT rating changed from "Strong Bu...
Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up
Sarepta Therapeutics Inc. SRPT reported on Tuesday that the first-quarter 2025 loss of $3.42 per share was missing the analyst consensus estimate of losses of 95 cents.
Sarepta Therapeutics: Lowered Elevidys Guidance Warrant Ratings Downgrade
Sarepta Therapeutics, Inc.'s stock is downgraded to Hold due to underperformance, safety concerns with ELEVIDYS, and increased expenses, despite strong long-term fundamentals. Q1 2025 results show mix...